PDS Biotechnology Corporation Receives Nasdaq Notice for Non-Compliance with Minimum Bid Price Rule
PDS Biotechnology Corporation (Nasdaq: PDSB), a biopharmaceutical company based in Princeton, New Jersey, announced that it has received a notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC, informing the Company that it is not currently in compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market.
Key Points for Investors
- Non-Compliance Notice: On July 30, 2026, PDS Biotechnology received a deficiency letter from Nasdaq stating that, for the last 30 consecutive business days, the closing bid price for the Company’s common stock has been below the required minimum of \$1.00 per share as stipulated by Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”).
- No Immediate Delisting: The notice does not result in the immediate delisting of the Company’s shares. PDS Biotechnology’s common stock will continue to trade on The Nasdaq Capital Market under the ticker symbol “PDSB” during the compliance period.
- Compliance Period: The Company has been granted a 180-calendar-day grace period, until January 26, 2027, to regain compliance. To do so, the Company’s common stock must close at or above \$1.00 per share for a minimum of 10 consecutive business days during this period.
- Potential for Extension: If the Company does not regain compliance by January 26, 2027, it may be eligible for a second 180-day grace period, provided it meets all other continued listing requirements for market value of publicly held shares and the initial listing standards for Nasdaq’s Capital Market, except for the minimum bid price requirement. The Company would also need to notify Nasdaq of its intent to cure the deficiency.
- Risk of Delisting: Failure to regain compliance within the allotted time frames would subject the Company’s common stock to delisting from Nasdaq. However, the Company would have the opportunity to appeal any delisting determination to a Nasdaq hearings panel.
- Potential Remedial Actions: The Company is actively monitoring the closing bid price of its common stock and may consider available options to regain compliance, including the possibility of implementing a reverse stock split. There is no assurance, however, that such actions would result in compliance with the Minimum Bid Price Requirement or other Nasdaq listing rules.
Implications for Shareholders
- Share Price Volatility: The receipt of a Nasdaq non-compliance notice is a material event and could result in increased volatility in PDSB’s share price as investors assess the risk of potential delisting and the Company’s ability to regain compliance.
- Potential Reverse Split: If the Company initiates a reverse stock split to increase its share price above \$1.00, this could affect the number of outstanding shares and the market value of individual holdings.
- Ongoing Operations: The Company’s operations are not immediately affected by the notice, but the risk of delisting could impact investor confidence, access to capital markets, and long-term strategic initiatives.
Other Relevant Information
- Company Details:
- Legal Name: PDS Biotechnology Corporation
- Formerly: Edge Therapeutics, Inc. (until 2009)
- Principal Address: 303A College Road East, Princeton, NJ 08540
- Phone: 800-208-3343
- Trading Symbol: PDSB
- Exchange: Nasdaq Capital Market
- Common Stock, par value \$0.00033 per share
- Executive Officer Signing: The report was signed by Frank, President and Chief Executive Officer, on July 31, 2026.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors are urged to conduct their own due diligence and consult with financial advisors before making any investment decisions. The information contained herein is based on the Company’s public filings and may be subject to change or update without notice. The Company has made no assurance of regaining compliance with Nasdaq’s listing requirements.
